"Muscarinic Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
| Descriptor ID |
D018727
|
| MeSH Number(s) |
D27.505.519.625.120.200.500 D27.505.696.577.120.200.500
|
| Concept/Terms |
Muscarinic Antagonists- Muscarinic Antagonists
- Antagonists, Muscarinic
- Antimuscarinics
- Antimuscarinic Agents
- Agents, Antimuscarinic
- Cholinergic Muscarinic Antagonists
- Antagonists, Cholinergic Muscarinic
- Muscarinic Antagonists, Cholinergic
|
Below are MeSH descriptors whose meaning is more general than "Muscarinic Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Muscarinic Antagonists".
This graph shows the total number of publications written about "Muscarinic Antagonists" by people in this website by year, and whether "Muscarinic Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 3 | 2 | 5 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 5 | 1 | 6 |
| 2017 | 1 | 4 | 5 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 6 | 3 | 9 |
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Muscarinic Antagonists" by people in Profiles.
-
Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease. Arch Gerontol Geriatr. 2025 Jan; 128:105629.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 Apr; 202(2):119-125.
-
Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong. Respir Med. 2024 02; 222:107516.
-
Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
-
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go? Eur Respir J. 2023 08; 62(2).
-
Muscarinic receptor activation in colon cancer selectively augments pro-proliferative microRNA-21, microRNA-221 and microRNA-222 expression. PLoS One. 2022; 17(6):e0269618.
-
Management of Life-Threatening Asthma: Severe Asthma Series. Chest. 2022 10; 162(4):747-756.
-
Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
-
Future concepts in bronchodilation for COPD: dual- versus monotherapy. Eur Respir Rev. 2021 Jun 30; 30(160).
-
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs Aging. 2021 07; 38(7):593-602.